Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents
(2009) In European Child & Adolescent Psychiatry 18(12). p.725-735- Abstract
- This 10-week study assessed the efficacy of atomoxetine in combination with psychoeducation compared to placebo and psychoeducation in the improvement of Quality of Life in Swedish stimulant-naive children and adolescents with attention deficit/hyperactivity disorder. A total of 99 patients were treated with atomoxetine (49 patients) or placebo (50 patients) for 10 weeks and assessed regarding broader areas of functioning using the Quality of Life measures Child Health and Illness Profile-Child Edition (CHIP-CE), Family Strain Index [FSI; equivalent to the Family Burden of Illness Module used in the study], Appraisal of Stress in Child-Rearing (ASCR), Five to fifteen (FTF), "I think I am" ("Jag tycker jag ar"), and Children's Depression... (More)
- This 10-week study assessed the efficacy of atomoxetine in combination with psychoeducation compared to placebo and psychoeducation in the improvement of Quality of Life in Swedish stimulant-naive children and adolescents with attention deficit/hyperactivity disorder. A total of 99 patients were treated with atomoxetine (49 patients) or placebo (50 patients) for 10 weeks and assessed regarding broader areas of functioning using the Quality of Life measures Child Health and Illness Profile-Child Edition (CHIP-CE), Family Strain Index [FSI; equivalent to the Family Burden of Illness Module used in the study], Appraisal of Stress in Child-Rearing (ASCR), Five to fifteen (FTF), "I think I am" ("Jag tycker jag ar"), and Children's Depression Rating Scale-Revised (CDRS-R) before and after the active treatment phase. Simultaneously, the patients' parents participated in a 4-session psychoeducation program. A statistically significant difference in favor of atomoxetine was seen in the improvement from baseline to study endpoint for the CHIP-CE domains "Achievement" and "Risk avoidance", for the FSI total score, for the ASCR section (I) domain "Child as a burden", for all FTF domains except for "Language and Speech", and for the CDRS-R total score. No difference between treatment groups was observed in the patient-assessed evaluation of self-esteem using the "I think I am" scale. Atomoxetine combined with psychoeducation had a positive effect on various everyday coping abilities of the patients as well as their families during 10 weeks of treatment, whereas the patients' self-image and the parents' image of the climate in the family were not significantly improved. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1505129
- author
- Svanborg, Par ; Thernlund, Gunilla LU ; Gustafsson, Per A. ; Hagglof, Bruno ; Schacht, Alexander and Kadesjo, Bjorn
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Broader efficacy, CHIP-CE, Quality of life, ADHD, Atomoxetine
- in
- European Child & Adolescent Psychiatry
- volume
- 18
- issue
- 12
- pages
- 725 - 735
- publisher
- Springer
- external identifiers
-
- wos:000271262600003
- scopus:70449532246
- pmid:19466476
- ISSN
- 1435-165X
- DOI
- 10.1007/s00787-009-0031-x
- language
- English
- LU publication?
- yes
- id
- 8901fdff-95a0-48ac-b6b0-7923edb95863 (old id 1505129)
- date added to LUP
- 2016-04-01 13:16:24
- date last changed
- 2022-03-13 23:07:45
@article{8901fdff-95a0-48ac-b6b0-7923edb95863, abstract = {{This 10-week study assessed the efficacy of atomoxetine in combination with psychoeducation compared to placebo and psychoeducation in the improvement of Quality of Life in Swedish stimulant-naive children and adolescents with attention deficit/hyperactivity disorder. A total of 99 patients were treated with atomoxetine (49 patients) or placebo (50 patients) for 10 weeks and assessed regarding broader areas of functioning using the Quality of Life measures Child Health and Illness Profile-Child Edition (CHIP-CE), Family Strain Index [FSI; equivalent to the Family Burden of Illness Module used in the study], Appraisal of Stress in Child-Rearing (ASCR), Five to fifteen (FTF), "I think I am" ("Jag tycker jag ar"), and Children's Depression Rating Scale-Revised (CDRS-R) before and after the active treatment phase. Simultaneously, the patients' parents participated in a 4-session psychoeducation program. A statistically significant difference in favor of atomoxetine was seen in the improvement from baseline to study endpoint for the CHIP-CE domains "Achievement" and "Risk avoidance", for the FSI total score, for the ASCR section (I) domain "Child as a burden", for all FTF domains except for "Language and Speech", and for the CDRS-R total score. No difference between treatment groups was observed in the patient-assessed evaluation of self-esteem using the "I think I am" scale. Atomoxetine combined with psychoeducation had a positive effect on various everyday coping abilities of the patients as well as their families during 10 weeks of treatment, whereas the patients' self-image and the parents' image of the climate in the family were not significantly improved.}}, author = {{Svanborg, Par and Thernlund, Gunilla and Gustafsson, Per A. and Hagglof, Bruno and Schacht, Alexander and Kadesjo, Bjorn}}, issn = {{1435-165X}}, keywords = {{Broader efficacy; CHIP-CE; Quality of life; ADHD; Atomoxetine}}, language = {{eng}}, number = {{12}}, pages = {{725--735}}, publisher = {{Springer}}, series = {{European Child & Adolescent Psychiatry}}, title = {{Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents}}, url = {{http://dx.doi.org/10.1007/s00787-009-0031-x}}, doi = {{10.1007/s00787-009-0031-x}}, volume = {{18}}, year = {{2009}}, }